Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 12/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217412 | 1.00 | SMO (0.55) | SMOHDAC1MAP4K4CKS1BSKP1 | |
| SCHEMBL12435071 | 0.90 | SMO (0.56) | SMOMAP4K4GPR119 | |
| SCHEMBL4166778 | 0.89 | SMO (0.70) | SMO | |
| SCHEMBL3638823 | 0.89 | SMO (0.70) | SMO | |
| SCHEMBL1102303 | 0.89 | SMO (0.70) | SMO | |
| SCHEMBL12435052 | 0.88 | SMO (0.45) | SMOMAP4K4GPR119 | |
| SCHEMBL2216812 | 0.86 | SMO (0.62) | SMO | |
| SCHEMBL2276477 | 0.81 | SMO (0.71) | SMO | |
| SCHEMBL12371761 | 0.81 | SMO (0.71) | SMO | |
| SCHEMBL2276481 | 0.81 | SMO (0.71) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358703-B1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | SMO, SHH, GLI1 | SMO 1/4885HDAC1 333/4885MAP4K4 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.